PROSER1

Summary

PROSER1 (proline and serine rich 1, HGNC:20291) is a protein-coding gene on chromosome 13q13.3, encoding Proline and serine-rich protein 1 (Q86XN7). Mediates OGT interaction with and O-GlcNAcylation of TET2 to control TET2 stabilization at enhancers and CpG islands (CGIs).

This gene encodes a conserved protein containing proline and serine rich regions. These regions may be important in protein-protein interactions.

Source: NCBI Gene 80209 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic disease (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 169 total
• MANE Select transcript: NM_025138

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20291
Approved symbol	PROSER1
Name	proline and serine rich 1
Location	13q13.3
Locus type	gene with protein product
Status	Approved
Aliases	bA50D16.2, FLJ12661
Ensembl gene	ENSG00000120685
Ensembl biotype	protein_coding
OMIM	620773
Entrez	80209

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 7 protein_coding, 6 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000352251, ENST00000418503, ENST00000436678, ENST00000468017, ENST00000484434, ENST00000492646, ENST00000496138, ENST00000602512, ENST00000602534, ENST00000602899, ENST00000625998, ENST00000897453, ENST00000897454, ENST00000897455, ENST00000922251

RefSeq mRNA: 2 — MANE Select: NM_025138 NM_025138, NM_170719

CCDS: CCDS45041, CCDS9368

Canonical transcript exons

ENST00000352251 — 13 exons

Exon	Start	End
ENSE00001602249	39012691	39014476
ENSE00001795498	39022326	39022412
ENSE00003461538	39023052	39023130
ENSE00003572812	39024473	39024556
ENSE00003573875	39031563	39031631
ENSE00003607500	39029281	39029375
ENSE00003640320	39026277	39026387
ENSE00003642079	39012083	39012233
ENSE00003657597	39017500	39017544
ENSE00003682056	39034131	39034196
ENSE00003788216	39028227	39028320
ENSE00003844266	39037198	39038089
ENSE00003845398	39009865	39011487

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 99.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.1496 / max 379.9191, expressed in 1807 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
136882	9.2428	1714
136878	7.7164	1603
136881	2.0522	872
136873	1.8331	904
136872	0.8445	525
136875	0.7809	473
136876	0.4923	246
136877	0.4562	237
136871	0.3575	185
136874	0.1452	49

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.91	gold quality
oocyte	CL:0000023	99.84	gold quality
ganglionic eminence	UBERON:0004023	90.31	gold quality
body of pancreas	UBERON:0001150	90.26	gold quality
colonic epithelium	UBERON:0000397	89.67	gold quality
skin of abdomen	UBERON:0001416	89.59	gold quality
cerebellar hemisphere	UBERON:0002245	89.59	gold quality
cerebellar cortex	UBERON:0002129	89.54	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.48	gold quality
skin of leg	UBERON:0001511	89.31	gold quality
placenta	UBERON:0001987	89.18	gold quality
rectum	UBERON:0001052	88.86	gold quality
granulocyte	CL:0000094	88.74	gold quality
lower esophagus mucosa	UBERON:0035834	88.15	gold quality
transverse colon	UBERON:0001157	88.10	gold quality
cerebellum	UBERON:0002037	88.03	gold quality
monocyte	CL:0000576	88.00	gold quality
upper lobe of left lung	UBERON:0008952	87.94	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.81	gold quality
mucosa of transverse colon	UBERON:0004991	87.68	gold quality
leukocyte	CL:0000738	87.67	gold quality
cortical plate	UBERON:0005343	87.67	gold quality
mononuclear cell	CL:0000842	87.66	gold quality
upper lobe of lung	UBERON:0008948	87.62	gold quality
zone of skin	UBERON:0000014	87.55	gold quality
ventricular zone	UBERON:0003053	87.55	gold quality
minor salivary gland	UBERON:0001830	87.26	gold quality
pancreas	UBERON:0001264	86.81	gold quality
spleen	UBERON:0002106	86.72	gold quality
right lobe of thyroid gland	UBERON:0001119	86.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

156 targeting PROSER1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3120-5P	100.00	65.56	965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910

Literature-anchored findings (GeneRIF, showing 2)

• Genomic regions have been identified demonstrating significant evidence for single nucleotide polymorphism linkage to Crohn’s disease on chromosomes 16q12.1 and 13q13.3, and suggestive evidence for linkage to ulcerative colitis on chromosome 19p12. (PMID:18246054)
• PROSER1 mediates TET2 O-GlcNAcylation to regulate DNA demethylation on UTX-dependent enhancers and CpG islands. (PMID:34667079)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	proser1	ENSDARG00000086302
mus_musculus	Proser1	ENSMUSG00000049504
rattus_norvegicus	Proser1	ENSRNOG00000010980

Protein

Protein identifiers

Proline and serine-rich protein 1 — Q86XN7 (reviewed: Q86XN7)

All UniProt accessions (2): Q86XN7, Q5JS36

UniProt curated annotations — full annotation on UniProt →

Function. Mediates OGT interaction with and O-GlcNAcylation of TET2 to control TET2 stabilization at enhancers and CpG islands (CGIs).

Subunit / interactions. Interacts with TET2 and OGT; this interaction mediates TET2 O-GlcNAcylation and stability by promoting the interaction between OGT and TET2. Interacts with KDM6A. Interacts with TET1.

Post-translational modifications. Glycosylated. Interaction with OGT leads to GlcNAcylation.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86XN7-1	1	yes
Q86XN7-2	2

RefSeq proteins (2): NP_079414, NP_733837 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028011	DUF4476	Domain
IPR042616	PROSER1	Family

Pfam: PF14771

UniProt features (15 total): region of interest 4, sequence conflict 3, compositionally biased region 3, sequence variant 2, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86XN7-F1	45.64	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 127 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, chr13q13, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, WTGAAAT_UNKNOWN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, LAIHO_COLORECTAL_CANCER_SERRATED_DN, SCGGAAGY_ELK1_02, FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP, GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN, BENPORATH_PROLIFERATION, STAT6_01, STK33_DN, STK33_NOMO_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

442 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PROSER1	NHLRC3	Q5JS37	664
PROSER1	CABP7	Q86V35	507
PROSER1	FREM2	Q5SZK8	497
PROSER1	QSER1	Q2KHR3	477
PROSER1	CCDC169	A6NNP5	475
PROSER1	STOML3	Q8TAV4	474
PROSER1	KIAA0825	Q8IV33	447
PROSER1	TOR1AIP1	Q5JTV8	433
PROSER1	SACS	Q9NZJ4	425
PROSER1	TMEM185B	Q9H7F4	418
PROSER1	NAA16	Q6N069	376
PROSER1	SERTM1	A2A2V5	375
PROSER1	ATOSA	Q32MH5	370
PROSER1	CSNK1A1L	Q8N752	365
PROSER1	VWA8	A3KMH1	356

IntAct

19 interactions, top by confidence:

A	B	Type	Score
NONO	SFPQ	psi-mi:“MI:0914”(association)	0.900
NONO	SERPINB7	psi-mi:“MI:0914”(association)	0.530
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
NONO	GYG2	psi-mi:“MI:0914”(association)	0.350
PSPC1	MCRIP1	psi-mi:“MI:0914”(association)	0.350
MAP7	TNPO2	psi-mi:“MI:0914”(association)	0.350
TOMM20	NUDT19	psi-mi:“MI:2364”(proximity)	0.270
HNF1B	BCL9	psi-mi:“MI:2364”(proximity)	0.270
PAX8	BCL9	psi-mi:“MI:2364”(proximity)	0.270
PAX9	BCL9	psi-mi:“MI:2364”(proximity)	0.270
SOX10	BCL9	psi-mi:“MI:2364”(proximity)	0.270
SOX2	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SOX5	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SOX6	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SP7	IGF2BP3	psi-mi:“MI:2364”(proximity)	0.270
TBR1	BCL9	psi-mi:“MI:2364”(proximity)	0.270
TLX3	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FHIP1B	MED19	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (41): PROSER1 (Proximity Label-MS), PROSER1 (Affinity Capture-MS), PROSER1 (Affinity Capture-MS), PROSER1 (Proximity Label-MS), PROSER1 (Proximity Label-MS), PROSER1 (Affinity Capture-RNA), PROSER1 (Affinity Capture-MS), PROSER1 (Proximity Label-MS), PROSER1 (Affinity Capture-MS), PROSER1 (Affinity Capture-MS), PROSER1 (Affinity Capture-MS), PROSER1 (Proximity Label-MS), PROSER1 (Proximity Label-MS), PROSER1 (Proximity Label-MS), PROSER1 (Proximity Label-MS)

ESM2 similar proteins: A0JME2, A5H447, A6NF01, A8CG34, E9Q3G8, F4ID16, G0SDP9, G5E8Z2, O08587, O15504, O88797, O95081, P20676, P49790, P49791, P52591, P52594, P98082, Q03173, Q0VA45, Q2TA45, Q4KLH5, Q5FVW4, Q5PRE5, Q5RB98, Q5SV85, Q5XGN1, Q5ZI22, Q5ZIE8, Q5ZM88, Q64028, Q640Z6, Q6P0U9, Q80WC7, Q86XN7, Q8CIC2, Q8K2K6, Q8K3Z9, Q8L7F7, Q8R080

Diamond homologs: Q5PRE5, Q86XN7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

169 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	129
Likely benign	8
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2183 predictions. Top by Δscore:

Variant	Effect	Δscore
13:39012078:CTTAC:C	donor_loss	1.0000
13:39012079:TTA:T	donor_loss	1.0000
13:39012080:TA:T	donor_loss	1.0000
13:39012081:A:AC	donor_gain	1.0000
13:39012081:A:AG	donor_loss	1.0000
13:39012082:C:CC	donor_gain	1.0000
13:39012082:CCTG:C	donor_gain	1.0000
13:39012229:ATAAA:A	acceptor_gain	1.0000
13:39012230:TAAA:T	acceptor_gain	1.0000
13:39012231:AAA:A	acceptor_gain	1.0000
13:39012231:AAAC:A	acceptor_loss	1.0000
13:39012232:AA:A	acceptor_gain	1.0000
13:39012232:AAC:A	acceptor_loss	1.0000
13:39012233:ACTA:A	acceptor_loss	1.0000
13:39012234:C:CA	acceptor_loss	1.0000
13:39012234:C:CC	acceptor_gain	1.0000
13:39017492:CTACT:C	donor_loss	1.0000
13:39017493:TACTT:T	donor_loss	1.0000
13:39017494:ACTTA:A	donor_loss	1.0000
13:39017495:CTTA:C	donor_loss	1.0000
13:39017496:TTA:T	donor_loss	1.0000
13:39017497:TA:T	donor_loss	1.0000
13:39017498:A:AC	donor_gain	1.0000
13:39017499:C:CA	donor_loss	1.0000
13:39017499:C:CC	donor_gain	1.0000
13:39017499:CT:C	donor_gain	1.0000
13:39017545:C:CC	acceptor_gain	1.0000
13:39017549:A:C	acceptor_gain	1.0000
13:39023050:A:AC	donor_gain	1.0000
13:39023051:C:CC	donor_gain	1.0000

AlphaMissense

5918 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:39029296:A:G	L87P	1.000
13:39029335:A:G	L74P	1.000
13:39031618:A:G	L42P	1.000
13:39034144:A:G	F33S	1.000
13:39028234:A:G	L121P	0.999
13:39028276:A:G	F107S	0.999
13:39029296:A:T	L87H	0.999
13:39029299:G:T	A86D	0.999
13:39029319:G:C	F79L	0.999
13:39029319:G:T	F79L	0.999
13:39029321:A:G	F79L	0.999
13:39029326:A:G	F77S	0.999
13:39029335:A:T	L74H	0.999
13:39031583:C:G	A54P	0.999
13:39031604:A:G	W47R	0.999
13:39031604:A:T	W47R	0.999
13:39031608:A:C	F45L	0.999
13:39031608:A:T	F45L	0.999
13:39031609:A:G	F45S	0.999
13:39031610:A:G	F45L	0.999
13:39034150:C:T	G31E	0.999
13:39037214:A:G	L10P	0.999
13:39026318:A:C	Y147D	0.998
13:39028245:G:C	C117W	0.998
13:39029320:A:G	F79S	0.998
13:39029335:A:C	L74R	0.998
13:39029338:A:C	I73R	0.998
13:39029338:A:T	I73K	0.998
13:39029362:A:T	V65D	0.998
13:39029373:T:A	K61N	0.998

dbSNP variants (sampled 300 via entrez): RS1000196293 (13:39019378 C>T), RS1000290460 (13:39028182 G>A,C,T), RS1000306303 (13:39034393 C>G), RS1000369874 (13:39033671 G>A), RS1000530719 (13:39018048 C>T), RS1000660589 (13:39027864 C>A), RS1000763337 (13:39035429 T>C,G), RS1000787924 (13:39009807 C>T), RS1000978094 (13:39016639 T>C), RS1001011706 (13:39031141 T>C), RS1001060976 (13:39029682 G>C,T), RS1001087122 (13:39024675 T>C), RS1001094070 (13:39023065 T>C), RS1001193173 (13:39011714 T>C), RS1001402850 (13:39017898 C>T)

Disease associations

OMIM: gene MIM:620773 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
syndromic disease	Limited	Autosomal recessive
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (2): syndromic disease (MONDO:0002254), neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003518_90	Daytime sleep phenotypes	5.000000e-06
GCST007511_14	Alzheimer’s disease (late onset)	4.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:1001870	late-onset Alzheimers disease

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D013577	Syndrome	C23.550.288.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	2
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
sodium arsenite	increases abundance, increases expression, affects cotreatment	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
abrine	decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cadmium	increases abundance, decreases expression	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Lead	affects expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	decreases methylation	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

227 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT00027456	PHASE2	COMPLETED	Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT00213447	Not specified	COMPLETED	T Cell Response in Hypersensitivity Syndrome
NCT02240888	Not specified	COMPLETED	Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
NCT02526082	Not specified	ACTIVE_NOT_RECRUITING	Long-term Follow-up of the Helsinki Businessmen Study
NCT02637518	Not specified	UNKNOWN	Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings
NCT02971072	Not specified	COMPLETED	Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy
NCT02974569	Not specified	COMPLETED	Improving Symptom Self-management in Adolescents & Young Adults With Cancer
NCT03265561	Not specified	COMPLETED	Spinal Infection Management With Structural Allograft
NCT04190342	Not specified	COMPLETED	Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients
NCT04874584	Not specified	COMPLETED	Culturally Tailored Nurse Coaching Study for Cancer Symptom Management
NCT04909489	Not specified	UNKNOWN	PDR and SKYD of Dyslipidemia’s Characteristics From the Oxidative Stress Enhancement Caused by Inhibition of Serine Metabolic Pathway
NCT05218122	Not specified	UNKNOWN	Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited
NCT05266118	Not specified	COMPLETED	Patient Reported Symptoms the First Week After Intensive Care Unit Discharge and up to Hospital Discharge
NCT05321966	Not specified	COMPLETED	The Effect of Video Training on Symptom Burden Patients Undergoing Hemodialysis Treatment
NCT05818748	Not specified	UNKNOWN	Effect Of Virtual Reality Distraction on Symptom Control and Anxiety in Children With Leukemia
NCT05837988	Not specified	UNKNOWN	Construction of Symptom Network in Maintenance Hemodialysis Patients
NCT06143436	Not specified	UNKNOWN	TCM Constitution, Pattern Types, and Disease Factors in Primary Lung Cancer.
NCT06222008	Not specified	UNKNOWN	Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution
NCT06412107	Not specified	COMPLETED	Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors
NCT06847360	Not specified	RECRUITING	Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
NCT07281300	Not specified	RECRUITING	Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
NCT07315672	Not specified	RECRUITING	Acupressure for Cough in Lung Cancer Survivors
NCT07479654	Not specified	NOT_YET_RECRUITING	AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease
NCT07495358	Not specified	NOT_YET_RECRUITING	Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy
NCT07576114	Not specified	RECRUITING	Comparison of Gluteal Muscle Activation and Core Strengthening in Dead Butt Syndrome Syndrome
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy